Microbiology Department, Santa Lucia University Hospital (HGUSL), Cartagena, 30202, Spain.
Clinical Analysis Department, Santa Lucia University Hospital (HGUSL), Cartagena, 30202, Spain.
Pharmacogenomics. 2020 Sep;21(14):1045-1059. doi: 10.2217/pgs-2020-0044. Epub 2020 Sep 8.
The crosstalk between the colon mucosa and the microbiota represents a complex and delicate equilibrium. Gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer (CRC) are associated with a state of altered microbiota composition known as dysbiosis, which seems to play a causative role in some of these illnesses. Recent reports have shown that the colorectal microbiome is responsible for the response and safety to treatments against CRC, especially immunotherapy, hence opening the possibility to use bacteria as a predictive marker and also as a therapeutic agent. The review objective is to summarize updated reports about the the implication of the colorectal microbiome in the development of CRC, in treatment response and its potential as a therapeutic approach.
结肠黏膜与微生物群之间的串扰代表了一种复杂而微妙的平衡。胃肠道疾病，如炎症性肠病和结直肠癌（CRC），与一种称为菌群失调的微生物组成改变状态有关，这种状态似乎在这些疾病中起着致病作用。最近的报告表明，结直肠微生物组负责对 CRC 的治疗反应和安全性，特别是免疫治疗，因此为将细菌用作预测标志物和治疗剂开辟了可能性。本综述的目的是总结关于结直肠微生物组在 CRC 发展、治疗反应及其作为治疗方法的潜在应用中的最新报告。
